Fampridin Zentiva

What Is Fampridin Zentiva and What Is It Used For?

Fampridin Zentiva is a prescription medicine containing fampridine (also known as 4-aminopyridine or dalfampridine), used to improve walking ability in adult patients with multiple sclerosis who have walking disability (typically patients with an EDSS score of 4-7). It is available as 10 mg prolonged-release tablets.

Fampridin Zentiva belongs to a class of medicines called potassium channel blockers. The active substance, fampridine, has been used in clinical and research settings for decades, with its ability to improve nerve conduction first recognised in the 1970s. The prolonged-release formulation was developed to provide steady plasma levels while reducing the risk of dose-related side effects, particularly seizures.

Multiple sclerosis is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath – the protective insulating layer that surrounds nerve fibres in the brain and spinal cord. When myelin is damaged (a process called demyelination), nerve signals are slowed or blocked entirely. This is the primary cause of many MS symptoms, including walking difficulty, fatigue, muscle weakness, and coordination problems.

Fampridine works by blocking voltage-gated potassium channels on the surface of demyelinated nerve fibres. In healthy nerves, the myelin sheath covers and insulates potassium channels. When myelin is lost, these channels become exposed and potassium ions leak out, disrupting the electrical impulse. By blocking these exposed channels, fampridine allows action potentials to propagate more efficiently along damaged nerve fibres, which can translate to improved walking speed and gait quality.

The European Medicines Agency (EMA) approved fampridine prolonged-release tablets in 2011 for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). The United States Food and Drug Administration (FDA) approved the same active substance under the brand name Ampyra in 2010. Fampridin Zentiva is a generic version, meaning it contains the same active ingredient in the same formulation and dosage as the reference product.

What conditions does fampridine treat?

Fampridine is specifically approved for improving walking in adult patients with multiple sclerosis who have walking disability. This typically means patients with an Expanded Disability Status Scale (EDSS) score between 4 and 7, which corresponds to a range from limited walking ability with or without aid to requiring a wheelchair for most activities. The medicine does not treat the underlying MS disease process itself and is not a cure for multiple sclerosis.

It is important to understand that fampridine is used alongside other MS treatments, not as a replacement. Patients typically continue their disease-modifying therapies (such as interferon beta, glatiramer acetate, dimethyl fumarate, or other agents) while taking fampridine for symptom management. The goal of fampridine therapy is specifically to improve mobility and quality of life by enhancing walking function.

How effective is Fampridin Zentiva?

The pivotal clinical trials (MS-F203 and MS-F204) enrolled over 540 patients with multiple sclerosis and walking disability. In these studies, approximately 35-43% of patients treated with fampridine were classified as consistent responders, meaning they showed reproducible improvements in walking speed. Responders showed an average improvement in walking speed of approximately 25% compared to their baseline, which translated to clinically meaningful improvements in daily activities.

Non-responders did not show significant improvement in walking speed compared to placebo. This “responder/non-responder” pattern is a characteristic feature of fampridine therapy and underscores the importance of early assessment. Clinical guidelines recommend evaluating treatment response within the first 2-4 weeks. If no improvement is observed, the medicine should be discontinued.

What Should You Know Before Taking Fampridin Zentiva?

Do not take Fampridin Zentiva if you have a history of seizures, moderate or severe kidney impairment, or if you are already taking another fampridine-containing product. Special caution is required in elderly patients, those with cardiac arrhythmias, and during pregnancy or breastfeeding.

Before starting treatment with Fampridin Zentiva, your doctor will carry out a thorough assessment of your medical history and current medications. Several important factors must be considered to ensure the medicine can be used safely. Below is a detailed overview of contraindications, warnings, and special populations.

Contraindications

Fampridin Zentiva must not be taken in the following situations:

• Allergy to fampridine or any of the other ingredients in the tablet (hydroxypropyl methylcellulose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, Opadry White)
• History of seizures (epilepsy or convulsions) – fampridine lowers the seizure threshold and can cause seizures even at therapeutic doses
• Moderate or severe kidney impairment (creatinine clearance less than 80 mL/min) – fampridine is primarily excreted by the kidneys, and reduced clearance leads to dangerously high blood levels
• Concurrent use of other fampridine-containing products – also known as 4-aminopyridine, which is sometimes used in compounding pharmacies. Taking two sources of fampridine significantly increases the risk of seizures and overdose

Warnings and Precautions

Talk to your doctor before taking Fampridin Zentiva if you have any of the following conditions or circumstances:

• Cardiac conditions: Patients with a history of cardiac arrhythmias or other significant heart conditions should be monitored closely. While the direct cardiac effects of fampridine are limited, potassium channel blockade could theoretically affect cardiac conduction in susceptible individuals
• Mild kidney impairment: Even mild reductions in kidney function (creatinine clearance 80-130 mL/min) may increase fampridine plasma levels. Your doctor may monitor your kidney function before and during treatment
• Infections: Urinary tract infections are more common in patients taking fampridine. Report symptoms such as painful urination, frequent urination, or fever to your doctor
• Immune system conditions: Patients with compromised immune systems, which is common in MS patients taking immunosuppressive therapies, should be aware of the increased infection risk
• Dizziness and balance problems: Fampridine can cause dizziness and balance disturbance, which may increase the risk of falls. This is particularly relevant for MS patients who already have impaired balance
• Trigeminal neuralgia: Cases of trigeminal neuralgia have been reported in patients taking fampridine. If you experience severe facial pain, contact your doctor

Pregnancy and Breastfeeding

There is limited data on the use of fampridine during pregnancy. Animal studies have shown some evidence of reproductive toxicity at doses higher than the recommended human dose. As a precautionary measure, Fampridin Zentiva is not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the unborn child. Women of childbearing potential should use effective contraception during treatment.

It is not known whether fampridine passes into human breast milk. Because many drugs are excreted in breast milk and because of the potential for serious adverse effects in the nursing infant, a decision should be made whether to discontinue breastfeeding or to discontinue the medicine, taking into account the importance of the medicine to the mother. Fampridin Zentiva should not be used during breastfeeding unless the healthcare provider determines that the benefit outweighs the risk.

Elderly Patients

Before starting treatment in elderly patients (65 years and older), kidney function should be assessed. Age-related decline in kidney function is common and may result in higher fampridine blood levels, increasing the risk of adverse effects including seizures. Dose adjustment is not possible with the 10 mg prolonged-release tablet, so the medicine should only be used in elderly patients if kidney function testing confirms adequate clearance (creatinine clearance above 80 mL/min).

Children and Adolescents

The safety and efficacy of Fampridin Zentiva in patients under 18 years of age have not been established. There is no relevant use of fampridine in the paediatric population for the approved indication (walking improvement in MS). The medicine should not be used in children and adolescents.

How Does Fampridin Zentiva Interact with Other Drugs?

Fampridin Zentiva should not be taken with other fampridine-containing products. Caution is needed with OCT2 inhibitors such as cimetidine, and with drugs that share the same renal transport pathway, including metformin, carvedilol, and propranolol. Always inform your doctor about all medicines you are taking.

Drug interactions with fampridine primarily relate to its renal elimination. Fampridine is eliminated mainly through the kidneys, with approximately 95.9% of the dose excreted unchanged in the urine. The organic cation transporter 2 (OCT2) is involved in the active renal secretion of fampridine. Therefore, medicines that affect OCT2 function or share the same transport pathway may interact with fampridine.

No formal clinical drug interaction studies have been conducted with all possible combinations. However, based on the pharmacokinetic profile and the known mechanisms of elimination, several clinically relevant interactions have been identified. The following table summarises the most important drug interactions:

Major Interactions

The most important interaction to be aware of is with other fampridine-containing products. Compounded formulations of 4-aminopyridine (the same active substance) are sometimes available from specialist pharmacies for various off-label neurological conditions. Using any other source of fampridine alongside Fampridin Zentiva could result in dangerously high blood levels, greatly increasing the risk of seizures and other toxic effects. This combination is strictly contraindicated.

Cimetidine, an H2 receptor antagonist used for gastric acid reduction, is a potent inhibitor of the OCT2 transporter. Co-administration with fampridine could significantly reduce renal clearance of fampridine, leading to elevated plasma levels. The EMA product information advises against concurrent use of fampridine with OCT2 inhibitors. If acid suppression is needed, consider alternative agents that do not inhibit OCT2, such as proton pump inhibitors (omeprazole, esomeprazole) or alternative H2 antagonists (ranitidine, famotidine).

Minor Interactions

Baclofen, a GABA-B receptor agonist commonly used as a muscle relaxant in MS patients, has its own seizure-lowering threshold properties, particularly during withdrawal. While no formal interaction study has been conducted, the theoretical additive effect on seizure threshold should be considered. No dose adjustment is required, but patients using both medicines should be monitored for signs of increased seizure susceptibility.

Disease-modifying therapies commonly used in MS – including interferon beta, glatiramer acetate, natalizumab, dimethyl fumarate, fingolimod, and teriflunomide – have different metabolic and elimination pathways from fampridine. No clinically significant interactions have been identified between fampridine and these agents, and they are commonly used together in clinical practice.

What Is the Correct Dosage of Fampridin Zentiva?

The recommended dose is one 10 mg prolonged-release tablet twice daily: one in the morning and one in the evening, approximately 12 hours apart. Do not take more than two tablets (20 mg) in 24 hours. The tablets must be swallowed whole without breaking, crushing, dissolving, or chewing.

The dosage of Fampridin Zentiva is straightforward but must be followed precisely. The prolonged-release formulation is designed to release the active substance slowly over several hours, maintaining therapeutic blood levels while minimising peak concentrations that could trigger seizures. Altering the tablet (by crushing or chewing) destroys this controlled-release mechanism, leading to rapid absorption and potentially dangerous blood levels.

Adults

The 10 mg twice-daily dose was established through phase II dose-finding studies, which showed that this regimen provided the optimal balance between efficacy and safety. Higher doses were associated with an unacceptable increase in seizure risk without proportional improvement in walking outcomes. There is no dose adjustment available for Fampridin Zentiva; the 10 mg prolonged-release tablet is the only approved strength and cannot be divided.

Treatment should be initiated by a physician experienced in the management of multiple sclerosis. An initial treatment period of 2 weeks is recommended to assess whether the patient responds to therapy. If no improvement in walking speed is observed after 2 weeks, the treatment should be discontinued. Reassessment may also be appropriate at 4 weeks if the initial response is unclear.

Children

Fampridin Zentiva is not indicated for use in children and adolescents under 18 years of age. There are no clinical data supporting its use in this population for the approved indication. Multiple sclerosis in children (paediatric MS) is relatively rare, and walking disability as a predominant symptom is less common in the paediatric population. No dose recommendation can be given.

Elderly

Elderly patients (65 years and older) may have age-related decline in kidney function that is not always reflected in standard blood creatinine measurements. Before starting Fampridin Zentiva in elderly patients, kidney function should be formally assessed using creatinine clearance calculation (e.g., Cockcroft-Gault equation) or measured glomerular filtration rate (GFR). Treatment may only proceed if creatinine clearance is confirmed to be above 80 mL/min. No dose adjustment is possible, as the tablet cannot be divided.

Missed Dose

If you forget to take a dose, do not take a double dose to make up for the missed one. Simply skip the missed dose and take the next tablet at the usual time. It is important to maintain the approximately 12-hour interval between doses. Taking tablets too close together increases the peak plasma concentration and the risk of dose-dependent side effects, particularly seizures.

Overdose

Overdose with fampridine is a serious medical emergency. Symptoms of overdose are dose-dependent and may include:

• Mild overdose: Sweating, tremor, confusion, memory impairment
• Moderate overdose: Seizures (the most clinically significant toxicity), status epilepticus
• Severe overdose: Cardiac arrest has been reported in cases of massive overdose with compounded 4-aminopyridine

What Are the Side Effects of Fampridin Zentiva?

The most common side effects of Fampridin Zentiva include urinary tract infections, insomnia, headache, dizziness, nausea, back pain, and balance disorder. Seizures are an uncommon but serious side effect. If you experience a seizure, stop the medicine immediately and contact your doctor.

Like all medicines, Fampridin Zentiva can cause side effects, although not everybody gets them. The side effects reported in clinical trials and post-marketing surveillance are listed below, grouped by frequency. The frequency categories are based on the following convention: very common (affects more than 1 in 10 people), common (affects 1 in 10 to 1 in 100 people), uncommon (affects 1 in 100 to 1 in 1,000 people), and rare (affects fewer than 1 in 1,000 people).

In the pivotal phase III clinical trials (MS-F203 and MS-F204), the overall incidence of adverse events was similar between fampridine and placebo groups for most side effects, with the exception of urinary tract infections and insomnia, which were notably more frequent in the fampridine group. The safety profile of fampridine has been well characterised over more than a decade of clinical use, and no new significant safety signals have emerged from post-marketing surveillance.

Most side effects of fampridine are mild to moderate in severity and tend to occur early in the course of treatment. Insomnia, for example, often improves as the body adjusts to the medicine over the first few weeks. However, certain side effects warrant immediate medical attention.

If you experience any side effects, including those not listed above, talk to your doctor or pharmacist. You can also report side effects directly via your national reporting system (e.g., the Yellow Card Scheme in the UK, MedWatch in the US, or the relevant national agency in your country). By reporting side effects, you can help provide more information on the safety of this medicine.

How Should You Store Fampridin Zentiva?

Store Fampridin Zentiva below 25°C in the original package to protect from moisture and light. Keep out of the sight and reach of children. Do not use after the expiry date printed on the packaging.

Proper storage of medicines is essential to maintain their effectiveness and safety. Fampridin Zentiva prolonged-release tablets should be stored at temperatures below 25°C (77°F). Do not refrigerate or freeze the tablets. Store them in the original blister packaging to protect them from moisture and light, as exposure to environmental humidity can affect the prolonged-release properties of the tablet coating.

Keep the medicine out of the sight and reach of children. Accidental ingestion of fampridine by a child could cause serious harm, including seizures. If a child accidentally takes one or more tablets, seek emergency medical assistance immediately.

Do not use Fampridin Zentiva after the expiry date which is stated on the carton and blister after “EXP”. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Travelling with your medicine

When travelling, keep Fampridin Zentiva in your hand luggage in its original packaging. Extreme temperatures in checked luggage holds can affect medicine stability. If travelling to a hot climate, consider using an insulated bag to keep the tablets below 25°C. Carry a copy of your prescription or a letter from your doctor in case you need to explain the medicine to customs authorities.

What Does Fampridin Zentiva Contain?

Each Fampridin Zentiva 10 mg prolonged-release tablet contains fampridine as the active ingredient. The tablet also contains excipients including hydroxypropyl methylcellulose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, and a white film coating (Opadry White).

Understanding the composition of your medicine can be important, particularly if you have known allergies or intolerances to specific pharmaceutical excipients. Below is a detailed breakdown of the active and inactive ingredients in Fampridin Zentiva 10 mg prolonged-release tablets.

Active Ingredient

The active substance is fampridine (also known internationally as 4-aminopyridine or dalfampridine). Each prolonged-release tablet contains exactly 10 mg of fampridine. This is the substance responsible for the therapeutic effect of the medicine – blocking potassium channels on demyelinated nerve fibres to improve nerve signal transmission.

Inactive Ingredients (Excipients)

The inactive ingredients play essential roles in the tablet’s structure, stability, and controlled-release mechanism:

• Hydroxypropyl methylcellulose (HPMC): Forms the matrix of the prolonged-release system. When the tablet contacts fluid in the gastrointestinal tract, HPMC swells and gradually releases the active substance over several hours
• Microcrystalline cellulose: A binder and filler that provides structural integrity to the tablet
• Colloidal anhydrous silica: A flow agent that ensures uniform distribution of ingredients during manufacturing
• Magnesium stearate: A lubricant that prevents the tablet from sticking to manufacturing equipment during compression
• Opadry White (film coating): Contains hypromellose, titanium dioxide (E171), and polyethylene glycol. Provides a protective coating, improves swallowability, and protects the tablet from moisture

Appearance

Fampridin Zentiva 10 mg prolonged-release tablets are white to off-white, oval-shaped, biconvex, film-coated tablets. They are supplied in blister packs containing 28 or 56 tablets. Not all pack sizes may be marketed in your country.